Figure 2
Mx1-Cre;Mib1f/f mice also develop an MPD. (A,B) Flow cytometric analysis of blood (A) and BM cells (B) from Mx1-Cre;Mib1+/f (left) and Mx1-Cre;Mib1f/f (right) mice 5 months after pIpC treatment (200 μg/every other day, 4 times). (C-E) Massive leukocyte infiltration (*) in the liver (C), lung (D), and kidney (E) (hematoxylin and eosin stain, ×200) of the Mx1-Cre;Mib1f/f mice. (E′) MPO/PCNA double immunostaining of the kidney (×200) from Mx1-Cre;Mib1f/f mice, 15 weeks after pIpC injection. Results are representative examples of 3 mutant mice. Scale bars: 100 μm.

Mx1-Cre;Mib1f/f mice also develop an MPD. (A,B) Flow cytometric analysis of blood (A) and BM cells (B) from Mx1-Cre;Mib1+/f (left) and Mx1-Cre;Mib1f/f (right) mice 5 months after pIpC treatment (200 μg/every other day, 4 times). (C-E) Massive leukocyte infiltration (*) in the liver (C), lung (D), and kidney (E) (hematoxylin and eosin stain, ×200) of the Mx1-Cre;Mib1f/f mice. (E′) MPO/PCNA double immunostaining of the kidney (×200) from Mx1-Cre;Mib1f/f mice, 15 weeks after pIpC injection. Results are representative examples of 3 mutant mice. Scale bars: 100 μm.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal